The use of combined hormonal contraceptives has been reported to increase the level of C-reactive protein (CRP). We assessed the effect of hormonal contraceptive use on inflammatory cytokines including CRP, monocyte chemotactic protein-1, soluble tumor necrosis factor (sTNF), interleukin-6 (IL-6), and soluble CD40 ligand. We used 79 female subjects (19 to 30 years old) who were combined oral co...

Background. Exercises with different intensities can cause changes in immune system factors and hormonal acute response. These changes may exceed the permissible limitations and weaken the system. Objectives. The purpose of this study was to compare the effect of an intensity aerobic and anaerobic training session on acute hormonal response and immune system factors. Methods. A total of...

INTRODUCTION In the postmenopausal period, an average of 25% of women will present symptomatic ovarian failure requiring hormonal replacement therapy. Estrogen can relieve vasomotor symptoms. Hormonal replacement therapy is generally not recommended for breast cancer patients due to the potential risk of tumor recurrence. To answer the questions about the safety of hormonal replacement therapy ...

In this paper we described the results of our studies on the baclophen (gamma aminobutyric acid (GABA)-B receptor agonist) inhibitory effect on the growth of experimental mammary cancer 16/C in mice and on the estimation of GABA level and GAD (glutamine acid decarboxylase--the key enzyme in GABA synthesis) activity after this treatment in mice. The experimental data are confronted with the esti...

Abstract Background Monitoring factors related to hormonal contraception (HC) use is essential evaluating public health strategies and promoting access contraception. We aimed examine municipal social indicators of HC at the population level, identify patterns inequality across Finnish municipalities. Methods identified all women (15–49 years) with a redeemed prescription in Finland 2017 ( n = ...

Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall times and positively impacts quality life. This case shows how apalutamide lowered tPSA level postponed metastatic disease.